Impairment Risk Associated with Investment Securities and Other Assets
First written in FY2017. 2 of 4 entries say "Materialised", first in FY2025-H1. Latest entry: FY2025.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2024, 4 years after the typical company in this theme (2020).
The whole theme swung hardest in 2019: 37 of 70 companies on the "Worse" side.
41 other companies' latest entry also says "Materialised".
- FY2025MaterialisedAnnual report
「During the consolidated fiscal year, the company recorded an impairment loss of ¥208.673 million on shares classified as other securities.」
The impairment risk relating to investment securities and other investments materialized during the fiscal year as an investment securities valuation loss of ¥208.673 million. - FY2025-H1MaterialisedAnnual report
「Impairment Loss on Investment Securities」
During the interim consolidated accounting period, the company recognized an investment securities valuation loss of ¥196.543 million as an extraordinary loss, and the impairment risk relating to investment securities and other investments materialized. - FY2019RestatedAnnual report
「Deterioration in future market conditions or poor performance by investees may require the recognition of valuation losses.」
The company continues to disclose the risk of valuation losses on investment securities and other investments due to market conditions and investee performance. - FY2017First statedAnnual report
「Deterioration in future market conditions or poor performance by investees may require the recognition of valuation losses.」
The company describes the risk of recognizing valuation losses on investments due to deteriorating market conditions or poor performance by investees.